Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Oct 2012

Nicot F, Saliou A, Raymond S, Sauné K, Dubois M, Massip P, Marchou B, Delobel P, Izopet J

Abstract excerpt

BACKGROUND: Recent data suggest that subjects harbouring low-frequency variants of HIV that are resistant to non-nucleoside reverse-transcriptase inhibitors (NNRTI) could suffer virological failure when treated with NNRTI-based therapy. Rilpivirine, a second-generation NNRTI, will be used in first-line regimen therapy, but the prevalence of minority variants that are resistant to rilpivirine is unknown....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to Nitriles

Share to Pyrimidines

Share to Reverse Transcriptase Inhibitors

Share to Rilpivirine

Source

Identifiers

PMID: 22818969
DOI: 10.1016/j.jcv.2012.06.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.PMID 22818969Read ↗

Minority resistant HIV-1 variants and the response to first-line NNRTI therapy.Semantic proximity Read ↗

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients.Semantic proximity Read ↗

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.Semantic proximity Read ↗

Assessment of Transmitted HIV-1 Drug Resistance Mutations Using Ultra- Deep Pyrosequencing in a Turkish Cohort.Semantic proximity Read ↗

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.Semantic proximity Read ↗

Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.Semantic proximity Read ↗

Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.Semantic proximity Read ↗

Primary HIV-1 Drug Resistant Minority Variants.Semantic proximity Read ↗

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.Semantic proximity Read ↗

Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.Semantic proximity Read ↗

Minority variants of drug-resistant HIV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.